TheNigerianVoice Online Radio Center


By NBF News
Listen to article

Chairman, Greenlife Pharmaceuticals, Dr. Obiora Chukwuka, has restated the company's resolve to partner with the National Agency for Food and Drug Administration and Control (NAFDAC) to rid the Nigerian market of fake, adulterated and unwholesome drugs.

Chukwuka, who stated this during a media chat Thursday, disclosed that in doing this, Greenlife Pharma had deployed the Mobile Authentication Service (MAS) to guard its flagship product, Lonart Ds, a brand of Artemether Lumenfantrine (ACT) antimalarial.

He said the product was recently counterfeited by unscrupulous elements in the society, stating that the deployment of the Mobile Authentication Service was to forestall a re-occurrence. 'It is in a bid to protect the integrity of the Lonart brand and by extension, the reputation of the company.'

'As a responsible corporate organisation, we remain very committed to the attainment of our vision of being in the vanguard of healthy living and a choice companion to our public.'

While disclosing that plans had been concluded to formally launch the MAS for Lonart DS before the end of September, he enthused that the effort would 'make it possible for its numerous consumers to confirm the genuineness of any pack bought. He, however, advised consumers to always carry out the verification exercise at the point of purchase.

Also speaking, Marking Manager, Pharm. Derrick Osonolu, stated that the deployment of the MAS on Lonart, a fast moving brand, is a Corporate Social Responsibility (CSR) effort by Greenlife to safeguard the lives of Nigerians. He, however, advised that samples of the brand currently in the market should not be discountenanced as unwholesome.

Explaining the procedure of MAS, Director, Sales and Marketing, Olugbenga Falabi, advised consumers of the product to always forward complaint of any fake suspected sachet to the call cantre number for onward transmission to NAFDAC, adding that the effort of saving lives should be everybody's concern.